📊 KNSA Key Takeaways
Is Kiniksa Pharmaceuticals International, plc (KNSA) a Good Investment?
Kiniksa maintains excellent financial health with a fortress balance sheet ($190M cash, zero debt), strong free cash flow generation (23.4% FCF margin), and consistent profitability (10.5% net margin). However, the pharmaceutical company faces critical headwinds: complete revenue stagnation (0% YoY growth), severely depressed returns on equity (3.7%) and assets (2.7%), suggesting mature products without pipeline growth.
Kiniksa presents a debt-free, cash-rich profile with double-digit operating margins and strong free cash flow (20% FCF margin), alongside a sharp EPS inflection. While revenue is flat YoY, disciplined costs and solid cash generation provide resilience and capacity to invest in growth. A return to top-line expansion could drive further operating leverage and returns.
Why Buy Kiniksa Pharmaceuticals International, plc Stock? KNSA Key Strengths
- Zero long-term debt with $190M cash reserves provides financial flexibility
- Excellent liquidity position (3.79x current ratio, 3.33x quick ratio) and strong balance sheet
- Robust free cash flow generation at 23.4% FCF margin despite flat revenue
- Profitable operations with acceptable 13.7% operating margin and 10.5% net margin
- Debt-free with strong liquidity (current ratio 3.79x; cash $165.6M)
- Robust free cash flow and cash conversion (OCF $138M; FCF margin 20.1%)
- Improving profitability and returns (EPS +225% YoY; 11.4% operating margin)
KNSA Stock Risks: Kiniksa Pharmaceuticals International, plc Investment Risks
- Flat revenue growth (0% YoY) critical concern for pharmaceutical sector requiring innovation
- Extremely low ROE (3.7%) and ROA (2.7%) indicate poor capital efficiency and value destruction
- Potential patent cliffs or pipeline issues implied by zero growth despite profitability
- 23 Form 4 filings may mask underlying business stagnation; insider activity alone insufficient without growth
- Flat revenue suggests potential growth stagnation or demand variability
- Potential product concentration with patent/exclusivity and reimbursement exposure
- Limited visibility into gross margin due to N/A gross profit reporting
Key Metrics to Watch
- Quarterly revenue growth trajectory and product pipeline advancement
- Return on equity and return on assets trend reversal
- Free cash flow sustainability and capital deployment decisions
- Gross margin trends and R&D spending efficiency
- Revenue growth (YoY)
- Free cash flow margin
Kiniksa Pharmaceuticals International, plc (KNSA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 23.4% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.79x current ratio provides a solid financial cushion.
KNSA Profit Margin, ROE & Profitability Analysis
KNSA vs Healthcare Sector: How Kiniksa Pharmaceuticals International, plc Compares
How Kiniksa Pharmaceuticals International, plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Kiniksa Pharmaceuticals International, plc Stock Overvalued? KNSA Valuation Analysis 2026
Based on fundamental analysis, Kiniksa Pharmaceuticals International, plc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Kiniksa Pharmaceuticals International, plc Balance Sheet: KNSA Debt, Cash & Liquidity
KNSA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Kiniksa Pharmaceuticals International, plc's revenue has grown significantly by 1,658% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.20 reflects profitable operations.
KNSA Revenue Growth, EPS Growth & YoY Performance
KNSA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $137.8M | $8.5M | $0.11 |
| Q3 2025 | $112.2M | -$3.9M | $-0.18 |
| Q2 2025 | $108.6M | -$3.9M | $-0.06 |
| Q1 2025 | $79.9M | $8.5M | $0.11 |
| Q3 2024 | $67.0M | -$3.9M | $-0.16 |
| Q2 2024 | $71.5M | $2.7M | $0.04 |
| Q1 2024 | $48.3M | -$12.3M | $-0.18 |
| Q3 2023 | $67.0M | -$11.2M | $-0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Kiniksa Pharmaceuticals International, plc Dividends, Buybacks & Capital Allocation
KNSA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Kiniksa Pharmaceuticals International, plc (CIK: 0001730430)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KNSA
What is the AI rating for KNSA?
Kiniksa Pharmaceuticals International, plc (KNSA) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 66% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KNSA's key strengths?
Claude: Zero long-term debt with $190M cash reserves provides financial flexibility. Excellent liquidity position (3.79x current ratio, 3.33x quick ratio) and strong balance sheet. ChatGPT: Debt-free with strong liquidity (current ratio 3.79x; cash $165.6M). Robust free cash flow and cash conversion (OCF $138M; FCF margin 20.1%).
What are the risks of investing in KNSA?
Claude: Flat revenue growth (0% YoY) critical concern for pharmaceutical sector requiring innovation. Extremely low ROE (3.7%) and ROA (2.7%) indicate poor capital efficiency and value destruction. ChatGPT: Flat revenue suggests potential growth stagnation or demand variability. Potential product concentration with patent/exclusivity and reimbursement exposure.
What is KNSA's revenue and growth?
Kiniksa Pharmaceuticals International, plc reported revenue of $214.3M.
Does KNSA pay dividends?
Kiniksa Pharmaceuticals International, plc does not currently pay dividends.
Where can I find KNSA SEC filings?
Official SEC filings for Kiniksa Pharmaceuticals International, plc (CIK: 0001730430) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KNSA's EPS?
Kiniksa Pharmaceuticals International, plc has a diluted EPS of $0.27.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KNSA a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Kiniksa Pharmaceuticals International, plc has a BUY rating with 66% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is KNSA stock overvalued or undervalued?
Valuation metrics for KNSA: ROE of 3.7% (sector avg: 15%), net margin of 10.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KNSA stock in 2026?
Our dual AI analysis gives Kiniksa Pharmaceuticals International, plc a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KNSA's free cash flow?
Kiniksa Pharmaceuticals International, plc's operating cash flow is $50.2M, with capital expenditures of $161.0K. FCF margin is 23.4%.
How does KNSA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 10.5% (avg: 12%), ROE 3.7% (avg: 15%), current ratio 3.79 (avg: 2).